Mela Sciences Inc (MELA) 3.23 $MELA Investors look to

New Post Public Reply Private Reply Replies (0) Message Board

Mar 16, 2015 at 2:05 PM

Mela Sciences Inc (MELA) 3.23 $MELA

Investors look to Lighten Up on Shares of MELA Sciences, Shares Down 5.6% (MELA)
Comtex SmarTrend(R) - Fri Mar 13, 10:47AM CDT
MELA Sciences (NASDAQ:MELA) is one of today's worst performing low-priced stocks, down 5.6% to $3.03 on 2.2x average daily volume. Thus far today, MELA Sciences has traded 482,000 shares, vs. average volume of 221,000 shares per day. The stock has underperformed the Dow (-5.6% to the Dow's -1.3%) and underperformed the S&P 500 (-5.6% to the S&P's -1.1%) during today's trading.
MELA: 3.23 (+0.19)

Weak On High Volume: Mela (MELA)
at The Street - Thu Mar 12, 9:01AM CDT
Trade-Ideas LLC identified Mela (MELA) as a weak on high relative volume candidate
MELA: 3.23 (+0.19)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 11:47AM CDT

BAK: 6.90 (+0.16), MELA: 3.23 (+0.19), ZGNX: 1.31 (+0.01), EOX: 0.90 (-0.11), MRD: 16.28 (-1.26), ULTR: 1.18 (+0.02), BLT: 13.29 (-0.12), RESN: 9.90 (-0.10), GBSN: 2.38 (+0.02), CYTX: 1.33 (+0.13), WRES: 1.00 (-0.05), MTL: 1.07 (-0.47), VRA: 15.54 (+0.29), CTP: 6.89 (-0.36), ENRJ: 1.52 (+0.02), CORT: 4.20 (+0.20), CBMG: 40.00 (+0.44), SPP: 1.90 (-0.10), CAPN: 6.05 (-0.31), SZYM: 2.79 (-0.24)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 8:11AM CDT

EXPR: 16.68 (+0.44), MELA: 3.23 (+0.19), ZGNX: 1.31 (+0.01), HABT: 31.02 (+1.06), MTL: 1.07 (-0.47), VRA: 15.54 (+0.29), GSAT: 3.29 (+0.21), BLRX: 1.98 (+0.02), SXL: 41.00 (-0.42)

Mela Sciences up big premarket on reimbursement codes for MelaFind system
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 7:11AM CDT

MELA: 3.23 (+0.19)

Traders smitten with tiny thinly-traded biotechs
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 9:44AM CST

GENE: 4.43 (-0.28), HTBX: 7.70 (+0.35), SGNL: 2.35 (-0.06), ROSG: 3.31 (-0.05), TTPH: 39.91 (+1.75), ONCY: 0.76 (-0.03), CLRX: 1.07 (unch), MELA: 3.23 (+0.19), AKAO: 10.12 (-0.15), WGBS: 4.65 (-0.30), EGRX: 42.91 (-3.18)

Global Point of Care Diagnostic Testing Markets Analysis 2014: Detailed Analysis of 25 Individual Country Markets
M2 - Thu Feb 05, 2:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/2mh8jd/point_of_care) has announced the addition of the "Global Point of Care Diagnostic Testing Markets Analysis 2014: Detailed Analysis of 25 Individual Country Markets" report to their offering. The report describes latest developments in the point of care testing market segment. It examines clinical instruments, devices and reagents and supplies as utilized in near-patient environments like hospital emergency rooms, critical care units, clinics and doctor's offices. The study defines the dollar volume of point of care sales and makes five year projections--both in the U.S. and worldwide--including Europe, Asia and Latin America. It also examines in detail the point of care sector for 25 individual country markets. A detailed summary of all important instruments in each clinical market is provided with emphasis on newly introduced products. Moreover, parallel areas where rapid detection is important using hand-held devices such as rapid detection of food pathogens and infectious diseases (MRSA, herpes simplex, avian flu, West Nile virus and typhoid) are discussed. Growth moderators and developing trends in point of care applications, as well as technology platform innovations and connectivity questions are examined in detail. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the point of care market in the U.S. and worldwide. Each company is discussed in depth, with a section on its history, product lines, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included. Key Topics Covered: 1. Overview 2. Overview of Diagnostic Testing Point of Care Markets 3. Summary Analysis of the Global POCT Market: Value, Growth Rates and Market Share 4. Analysis of the U.S. POCT Market: Value, Growth Rates and Market Share 5. Analysis of the European POCT Market: Value, Growth Rates and Market Shares 6. Analysis of the POCT Markets for Japan, China and India: Value, Growth Rates and Market Share 7. Analysis of the Rest of World (ROW) POCT Market: Value, Growth Rates and Market Share 8. Review of the Market Segments, Reagents and Equipment 9. POCT: Growth Regulators 10. Business Trends in the POC Sector 11. Technology Platform Innovations in POCT 12. Data Management and Connectivity 13. Corporate Profiles 14. POCT Sector Trends and Forecasts 15. New Entrants to the Point of Care Market Selection of 30 Companies: Click the link below to view the full extensive list featured in this report - Abaxis, Inc. - Abbott Laboratories - Acrongenomics - AgaMatrix - Augurix Diagnostics Ltd. - Axis-Shield Plc (Alere) - Axxin - Bayer Corp - Chembio Diagnostic, Inc. - Home Diagnostics (Nipro Diagnostics) - Medix Biochemica - MedMira Laboratories - MELA Sciences (Formerly Electro-Optical Sciences) - A. Menarini Diagnostics - Meretek Diagnostics Group - Nexus/ITC - Nova Biomedical - OraSure Technologies, Inc. - Orion Diagnostica - Polymedco, Inc. - Polymer Technology Systems, Inc. - Prima Biomedical Company - QBC Diagnostics - Qualigen - Selfcare, Inc. - Shanghai Ruicare Medical Co., Ltd. - Shenzhen Fitconn Technology Co., Ltd. - Siemens AG - Siloam Biosciences, Inc. - V?samed, Inc. For more information visit http://www.researchandmarkets.com/research/2m...nt_of_care
ABT: 47.77 (+0.89), MELA: 3.23 (+0.19), ABAX: 64.27 (+1.39), OSUR: 7.25 (-0.10)

MELA Sciences CEO Michael R. Stewart to Present at the Eighth Annual OneMedForum January 13 at 2 p.m.
GlobeNewswire - Thu Jan 08, 5:07PM CST
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind(R) system, a non-invasive software-driven image analysis device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced that MELA Sciences' CEO Michael R. Stewart will present at the OneMedForum at the Marriott Marquis, San Francisco on January 13 at 2:00 p.m. PST.
MELA: 3.23 (+0.19)

Mela Sciences up in early trading
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 10:45AM CST

MELA: 3.23 (+0.19)

MELA Sciences elects Michael R. Stewart as its CEO
M2 - Thu Nov 20, 5:43AM CST
Software image analysis company MELA Sciences (NasdaqCM:MELA) reported on Wednesday the appointment of Michael R. Stewart as its president and chief executive officer with effect from 15 December 2014.
MELA: 3.23 (+0.19)

MELA Sciences Names Michael R. Stewart Its Next President and CEO
GlobeNewswire - Wed Nov 19, 7:07AM CST
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind system, a non-invasive software-driven image analysis device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced that its Board of Directors has named Michael R. Stewart, 57, as the company's next President and Chief Executive Officer, effective December 15. Mr. Stewart, who joined the MELA Sciences Board of Directors in August 2014, will remain a member of the board.
MELA: 3.23 (+0.19)

MELA Sciences announces 69% drop in net loss in Q3 2014
M2 - Fri Nov 14, 6:29AM CST
Medical device company MELA Sciences (NasdaqCM:MELA) stated on Thursday its net loss of USD2.3m (USD0.44 per basic and diluted share) for the three months ended 30 September 2014.
MELA: 3.23 (+0.19)

MELA Sciences' (MELA) CEO Rose Crane on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 8:59PM CST

MELA: 3.23 (+0.19)

MELA Sciences EPS of -$0.44
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:08PM CST

MELA: 3.23 (+0.19)

MELA Sciences Reports Third Quarter 2014 Financial Results
GlobeNewswire - Wed Nov 12, 3:06PM CST
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFindsystem, a non-invasive software-driven image analysis device intended to provide a dermatologist with objective data of clinically irregular pigmented moles when they choose to obtain additional info to help them decide whether or not to biopsy (at the most curable and cost-effective stage), today announced financial results for the three and nine months ended September 30, 2014.
MELA: 3.23 (+0.19)

MELA Sciences to Report Third Quarter 2014 Financial Results on Wednesday, November 12
GlobeNewswire - Wed Nov 05, 7:00AM CST
MELA Sciences, Inc. (Nasdaq:MELA), developer of MelaFind, a non-invasive software-driven image analysis device intended to provide a dermatologist with objective data of clinically irregular pigmented moles when they choose to obtain additional info to help them decide whether or not to biopsy (at the most curable and cost-effective stage), will release third quarter 2014 financial results on Wednesday, November 12, after the market close. MELA Sciences President and Chief Executive Officer, Rose Crane, and Robert Cook, Chief Financial Officer, will host a conference call at 4:30pm Eastern Time to review the Company's progress and answer questions.
MELA: 3.23 (+0.19)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Faces Legal Questions After CFO Exit and Losses

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Larry Ellison's Moves Signal Confidence in Oracle's Future

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

PureHealth's Acid Reflux Solutions: An Investor's Insight

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

SMPL Faces Legal Drama: What Investors Need to Know

Investors Swim Against the Current With SMPL Picture this: You’re sipping your morning coffee, glancing through stocks, only to choke on your bagel when The Simply Good Foods Company (NASDAQ: SMPL) pops up with some less-than-palatable news. A class action is brewing, shouting out to investors who took the bait from October 24, 2024, to April 8, 2026. If you’re one of...

USPS Honors 150 Years of the U.S. Coast Guard Academy

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Pizza: The Unlikely Symbol of Universal Togetherness

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...